Answers are grounded in this paper and cite their sources.
Nucleic acid amplification tests (NAATs) are currently the most sensitive diagnostic tool for detecting human immunodeficiency virus (HIV) and are considered the gold standard for disease diagnosis and monitoring antiretroviral therapy. Nucleic acid detection requires sample treatment for viral lysis. In this work, we evaluated the effectiveness of thermal (56 °C, 65 °C and 95 °C) and chemical treatments (QuickExtract solution, FastAmp solution, 1% or 0.1% Triton X-100) for HIV-1 lysis in whole blood and saliva. Treatment at 95 °C for 5 min or with 1% Triton X-100 for 2.5 min at room temperature were both highly effective at lysing HIV-1 in whole blood and saliva. We evaluated the compatibility of 1% Triton X-100 treatment for point-of-care nucleic acid detection by testing treated blood and saliva samples using a CRISPR-Cas13a-based lateral flow assay (LFA). Whole blood samples treated with 1% Triton X-100 showed similar analytical sensitivity as those treated at 95 °C while saliva samples treated with 1% Triton X-100 showed slightly higher analytical sensitivity than those treated at 95 °C. In summary, treatment with 1% Triton X-100 is an effective method for rapid HIV-1 lysis that does not require equipment, making it a promising approach for point-of-care testing.
No takes yet. Share an insight, caveat, or question.
Gonzalez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: